Skip to content
    Real-World Studies

    Pembrolizumab-Induced Permanent Hypothyroidism

    Koffka et alInternational journal of cancer

    In a retrospective real-world cohort study evaluating patients with gynecologic malignancies and melanoma treated with at least three cycles of pembrolizumab, permanent hypothyroidism was identified as a frequent immune-related adverse event (irAE), occurring in 16.0% (30/188) of patients. Thyrotoxicosis developed in 24.5% (46/188) and de novo hypothyroidism in 17.6% (33/188) of the cohort. Among patients who developed overt thyrotoxicosis, 71% subsequently transitioned into permanent hypothyroidism requiring lifelong hormone replacement.
    Permanent hypothyroidism typically manifested early during treatment, with a median onset of 15 weeks compared to 26 weeks for transient thyroid dysfunction. No new cases of permanent hypothyroidism developed beyond 50 weeks of therapy. Nearly all permanent cases presented with overt thyroid dysfunction upon initial detection (29 of 30 cases), although the majority of affected patients remained asymptomatic. Clinical management was largely straightforward, with most cases presenting as mild and adequately controlled with oral levothyroxine replacement.
    Prior chemotherapy exposure was identified as an independent risk factor, conferring a significantly higher rate of permanent hypothyroidism compared to patients without prior chemotherapy (33% vs. 11%; p = 0.001). Other baseline characteristics, including patient age, sex, tumor stage, treatment setting, and other concurrent or prior systemic therapies, demonstrated no significant predictive value. Furthermore, the emergence of permanent hypothyroidism did not confer any prognostic advantage or disadvantage, showing no statistically significant association with progression-free survival, recurrence-free survival, or overall survival. Based on these temporal dynamics, routine cycle-based thyroid function monitoring is supported through the first 12 months of pembrolizumab therapy, with closer clinical vigilance indicated for patients previously treated with cytotoxic chemotherapy.

    Key Takeaways

    • Permanent hypothyroidism occurred in 16.0% (30/188) of patients receiving pembrolizumab, developing at a median of 15 weeks (with zero new cases observed after 50 weeks), and 71% of overt thyrotoxicosis cases transitioned to permanent hypothyroidism.
    • Prior chemotherapy exposure was strongly associated with an increased incidence of permanent hypothyroidism compared to no prior chemotherapy (33% vs. 11%; p = 0.001), whereas age, sex, tumor stage, and treatment setting showed no association.
    • The development of permanent hypothyroidism did not correlate with progression-free survival, recurrence-free survival, or overall survival.
    Read the original sourceInternational journal of cancer